Xu Y - Search Results

1

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.

Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH, Wang F. Wang ZX, et al. Among authors: xu rh, xu y. Cancer Cell. 2022 Mar 14;40(3):277-288.e3. doi: 10.1016/j.ccell.2022.02.007. Epub 2022 Mar 3. Cancer Cell. 2022. PMID: 35245446 Free article. Clinical Trial.

2

ROR nuclear receptors: structures, related diseases, and drug discovery.

Zhang Y, Luo XY, Wu DH, Xu Y. Zhang Y, et al. Among authors: xu y. Acta Pharmacol Sin. 2015 Jan;36(1):71-87. doi: 10.1038/aps.2014.120. Epub 2014 Dec 15. Acta Pharmacol Sin. 2015. PMID: 25500868 Free PMC article. Review.

3

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.

Huang CY, Wang L, Feng CJ, Yu P, Cai XH, Yao WX, Xu Y, Liu XK, Zhu WJ, Wang Y, Zhou J, Lu Y, Wang YS. Huang CY, et al. Among authors: xu y. Oncotarget. 2016 Oct 11;7(41):66480-66490. doi: 10.18632/oncotarget.5515. Oncotarget. 2016. PMID: 26624882 Free PMC article.

4

Adjuvant Therapeutic Modalities in Primary Small Cell Carcinoma of Esophagus Patients: A Retrospective Cohort Study of Multicenter Clinical Outcomes.

Zou B, Li T, Zhou Q, Ma D, Chen Y, Huang M, Peng F, Xu Y, Zhu J, Ding Z, Zhou L, Wang J, Ren L, Yu M, Gong Y, Li Y, Chen L, Lu Y. Zou B, et al. Among authors: xu y. Medicine (Baltimore). 2016 Apr;95(17):e3507. doi: 10.1097/MD.0000000000003507. Medicine (Baltimore). 2016. PMID: 27124057 Free PMC article.

5

Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.

Huang J, Zhao Y, Xu Y, Zhu Y, Huang J, Liu Y, Zhao L, Li Z, Liu H, Wang QL, Qi X. Huang J, et al. Among authors: xu y. Oncotarget. 2016 Jun 7;7(23):34824-31. doi: 10.18632/oncotarget.9189. Oncotarget. 2016. PMID: 27166187 Free PMC article.

6

Postoperative chemoradiotherapy improves survival in patients with stage II-III esophageal squamous cell carcinoma: An analysis of clinical outcomes.

Zou B, Pang J, Liu Y, Xu Y, Li L, Zhou L, Zhu J, Huang M, Wang J, Ren L, Gong Y, Lu Y, Chen L, Peng F. Zou B, et al. Among authors: xu y. Thorac Cancer. 2016 Sep;7(5):515-521. doi: 10.1111/1759-7714.12355. Epub 2016 May 6. Thorac Cancer. 2016. PMID: 27766781 Free PMC article.

7

Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?

Zou B, Tu Y, Liao D, Xu Y, Wang J, Huang M, Ren L, Zhu J, Gong Y, Liu Y, Zhou L, Zhou X, Peng F, Lu Y. Zou B, et al. Among authors: xu y. Thorac Cancer. 2020 Mar;11(3):631-639. doi: 10.1111/1759-7714.13307. Epub 2020 Jan 14. Thorac Cancer. 2020. PMID: 31943824 Free PMC article.

8

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.

Wei H, Zhou X, Yang H, Gong Y, Wang J, Xu Y, Zhou L, Xue J, Zou B, Zhang Y, Zhu J, Peng F, Huang M, Lu Y, Liu Y. Wei H, et al. Among authors: xu y. J Cancer Res Clin Oncol. 2022 Oct;148(10):2589-2598. doi: 10.1007/s00432-021-03831-z. Epub 2021 Oct 20. J Cancer Res Clin Oncol. 2022. PMID: 34669037

9

MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.

Zhou M, Wang J, Ouyang J, Xu JY, Chen B, Zhang QG, Zhou RF, Yang YG, Shao XY, Xu Y, Chen YM, Fan XS, Wu HY. Zhou M, et al. Among authors: xu jy, xu y. Tumour Biol. 2014 Jul;35(7):6757-62. doi: 10.1007/s13277-014-1907-z. Epub 2014 Apr 11. Tumour Biol. 2014. PMID: 24719189

10

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.

Zhang Y, Wang W, Wang Y, Xu Y, Tian Y, Huang M, Lu Y. Zhang Y, et al. Among authors: xu y. J Thorac Oncol. 2016 May;11(5):e59-e62. doi: 10.1016/j.jtho.2015.12.102. Epub 2015 Dec 25. J Thorac Oncol. 2016. PMID: 26724472 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66,883 results

Search Page